Altimmune (ALT) Stock Price, News & Analysis

Company Overview

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Key Stats

• Today's Range: $3.58 to $3.72
• 50-Day Range: $3.50 to $7.71
• 52-Week Range: $2.90 to $11.16
• Volume: 1.80 million shs
• Average Volume: 3.61 million shs
• Market Capitalization: $292.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.20
• Consensus Rating: Moderate Buy

Altimmune Stock Analysis - MarketRank™

Altimmune scored higher than 45% of companies evaluated by MarketBeat, and ranked 591st out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Altimmune has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 5 buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Altimmune has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Altimmune are expected to grow in the coming year, from ($1.35) to ($0.96) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Altimmune is -2.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Altimmune is -2.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Altimmune has a P/B Ratio of 2.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

34.64% of the outstanding shares of Altimmune have been sold short.

Short Interest Ratio / Days to Cover

Altimmune has a short interest ratio ("days to cover") of 5.1.

Change versus previous month

Short interest in Altimmune has recently decreased by 9.88%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Altimmune does not currently pay a dividend.

Dividend Growth

Altimmune does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

34.64% of the outstanding shares of Altimmune have been sold short.

Short Interest Ratio / Days to Cover

Altimmune has a short interest ratio ("days to cover") of 5.1.

Change versus previous month

Short interest in Altimmune has recently decreased by 9.88%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: 0.27

News Sentiment

Altimmune has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Altimmune this week, compared to 5 articles on an average week.

Search Interest

Only 32 people have searched for ALT on MarketBeat in the last 30 days. This is a decrease of -30% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Altimmune to their MarketBeat watchlist in the last 30 days. This is a decrease of -70% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Altimmune insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.10% of the stock of Altimmune is held by insiders.

Percentage Held by Institutions

78.05% of the stock of Altimmune is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ALT Stock Analysis - Frequently Asked Questions

How have ALT shares performed this year?

Altimmune's stock was trading at $7.21 at the start of the year. Since then, ALT shares have decreased by 49.9% and is now trading at $3.61.

How were Altimmune's earnings last quarter?

Altimmune, Inc. (NASDAQ:ALT) announced its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.09. The firm had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0 million. Altimmune had a negative net margin of 451,200.00% and a negative trailing twelve-month return on equity of 65.44%.
Read the conference call transcript.

When did Altimmune's stock split?

Altimmune shares reverse split on the morning of Friday, September 14th 2018.The 1-30 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Who are Altimmune's major shareholders?

Altimmune's top institutional shareholders include Caitong International Asset Management Co. Ltd (0.30%), Baader Bank Aktiengesellschaft (0.04%), Envestnet Asset Management Inc. (0.04%) and Concurrent Investment Advisors LLC (0.03%). Insiders that own company stock include Vipin K Garg, David Drutz, Matthew Scott Harris, Gregory L Weaver and Wayne Pisano.
View institutional ownership trends.

How do I buy shares of Altimmune?

Shares of ALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Altimmune own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Altimmune investors own include Invesco QQQ (QQQ), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Pfizer (PFE) and SPDR S&P 500 ETF Trust (SPY).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 8/02/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALT
• CIK: 1326190
• Web: altimmune.com
• Phone: (240) 654-1450
• Fax: 410-269-2601
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Altimmune: $18.20
• High Price Target: $26.00
• Low Price Target: $12.00
• Potential Upside/Downside: +404.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.26)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$95.06 million
• Net Margins: -451,200.00%
• Pretax Margin: -454,604.97%
• Return on Equity: -65.44%
• Return on Assets: -58.43%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.85
• Quick Ratio: 15.85

Sales & Book Value

• Annual Sales: $20 thousand
• Price / Sales: 14,640.36
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.74 per share
• Price / Book: 2.07

Miscellaneous

• Outstanding Shares: 81,110,000
• Free Float: 77,782,000
• Market Cap: $292.81 million
• Optionable: Optionable
• Beta: -0.01